Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 11/20 | 0.54 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18984674 | 0.85 | MEN1 (0.59) | KDM4EMAP4K4HTR1ASLC6A2SLC6A4 | |
| SCHEMBL30108336 | 0.83 | MEN1 (0.54) | TRPA1HSPB1L3MBTL1KDM4EMAP4K4 | |
| SCHEMBL28443118 | 0.83 | GRM4 (0.48) | L3MBTL1KDM4ESLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28115709 | 0.83 | HTR1A (0.49) | TRPA1L3MBTL1KDM4EHTR1ASLC6A2 | |
| SCHEMBL2427966 | 0.83 | POLB (0.46) | TRPA1HSPB1L3MBTL1KDM4ESLC6A4 | |
| SCHEMBL24741603 | 0.83 | MEN1 (0.54) | TRPA1HSPB1L3MBTL1KDM4EMAP4K4 | |
| SCHEMBL28115267 | 0.82 | KDM4E (0.43) | TRPA1L3MBTL1KDM4EMEN1KMT2A | |
| SCHEMBL28115716 | 0.81 | TRPA1 (0.48) | TRPA1L3MBTL1KDM4E | |
| SCHEMBL3288850 | 0.80 | KDM4E (0.47) | TRPA1L3MBTL1KDM4EMEN1KMT2A | |
| SCHEMBL30689339 | 0.80 | ALOX5AP (0.41) | KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9855269-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| EP-2363128-A2 | Indole modulators of ATP-binding cassette transporters | Vertex Pharmaceuticals Incorporated (US) | 2011-09-07 | — | — | EP | disclosed |
| EP-1620105-A1 | (6-(PHENOXY)-PYRIDO[3,4-D]PYRIMIDIN-2-YL)-AMINE DERIVATIVES AS P38 KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS SUCH AS RHEUMATOID ARTHRITIS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004091625-A1 | (6-(PHENOXY)-PYRIDO`3,4-D! PYRIMIDIN-2-YL)-AMINE DERIVATIVES AS P38 KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORYY CONDITIONS SUCH AS RHEUMATOIS ARTRITIS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | FLT4, FLT1, KDR | TRPA1 4470/4885HSPB1 4668/4885L3MBTL1 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.